A 2026 meta-analysis found a 3.5% biochemical recurrence rate in hypogonadal men on TRT after radical prostatectomy. This primer explains what that means for patients.
A 2026 meta-analysis found a 3.5% biochemical recurrence rate in hypogonadal men on TRT after radical prostatectomy. This primer explains what that means for patients.
For carefully selected men who have had a radical prostatectomy (surgical removal of the prostate) and are now hypogonadal (meaning their testosterone has dropped low enough to cause symptoms), the current evidence is cautiously reassuring. A 2026 meta-analysis published in Andrology found a pooled biochemical recurrence rate of just 3.5% (95% CI: 1.5–8.5%) among hypogonadal men who received testosterone replacement therapy (TRT) after radical prostatectomy [1].
Biochemical recurrence, or BCR, is the term clinicians use when PSA (prostate-specific antigen, a protein made by prostate tissue) starts rising again after surgery, which can signal that some cancer cells remain active. A 3.5% pooled rate across 398 men followed for an average of nearly 30 months is a signal worth paying attention to [1].
Two broader systematic reviews add useful context:
Put plainly: across multiple reviews, the cancer-return signal in carefully chosen surgical patients on TRT has been low. The evidence is not yet definitive, but it is more reassuring than the decades-old assumption that testosterone and prostate cancer simply cannot coexist. Understanding why that assumption existed, and why the science has shifted, requires a closer look at how testosterone actually affects prostate tissue.
Prostate cancer treatment, not the cancer itself, is usually the culprit. Surgery, radiation, and especially androgen deprivation therapy (ADT, a drug-based approach that chemically suppresses testosterone to starve any remaining cancer cells) can all disrupt the hormonal axis that keeps testosterone production running.
The pituitary-gonadal axis is the body's testosterone command chain: the pituitary gland in your brain sends a signal called LH (luteinizing hormone) down to the testes, telling them to produce testosterone. ADT interrupts that chain at multiple points. Even radical prostatectomy alone, without ADT, can disturb this signaling through surgical stress and the physiological aftermath of major pelvic surgery [4].
When ADT is involved, testosterone suppression is the intended effect, but recovery after stopping ADT is far from certain. A 2019 retrospective study in Investigative and Clinical Urology found that only 55.2% of men recovered out of the hypogonadal range after ADT withdrawal, and older age, longer ADT duration, and higher baseline SHBG all predicted slower or incomplete recovery [5]. Men treated with ADT for more than 18 months recovered testosterone to normal levels at roughly one-third the rate of men treated for 18 months or less [5].
The lived experience of low testosterone after treatment looks like this:
A full picture of these low testosterone symptoms in men matters because they are often misread as normal aging or post-cancer depression, delaying an evaluation that your hormone lab report could clarify quickly. Knowing why testosterone falls is the first step; the harder question is whether restoring it poses any real cancer risk.
For decades, the answer seemed obvious: yes. In 1941, Huggins and Hodges showed that castrating men with advanced prostate cancer caused tumors to shrink, and the medical community drew a logical but ultimately oversimplified conclusion: more testosterone means faster tumor growth. That belief hardened into dogma, and TRT after any prostate cancer diagnosis became nearly unthinkable.
The saturation model changed that framework. Proposed by Morgentaler and Traish in a landmark review in European Urology, the model rests on a straightforward biochemical principle: prostate cells contain androgen receptors, which are the molecular "on switches" that testosterone must bind to trigger cell activity. Those receptors reach full occupancy at testosterone concentrations well below the normal physiologic range [6]. Once every receptor is occupied, adding more testosterone produces little additional effect on prostate tissue, the same way a sponge absorbs water up to a point and then stops, no matter how much more you pour.
Put plainly: once testosterone is above a certain low threshold, raising it further does not meaningfully accelerate prostate activity.
What this means in practice:
The saturation model does not eliminate concern entirely. It does, however, explain why the old rule, "any testosterone is dangerous," was never consistent with the underlying biology. The more precise question is whether the clinical data support acting on that updated biology, and that is where the new meta-analysis is worth examining carefully.
The 2026 meta-analysis in Andrology pulled together seven retrospective studies covering 398 hypogonadal men who received testosterone therapy after radical prostatectomy, with a mean follow-up of 29.6 months. The pooled biochemical recurrence rate, the reappearance of PSA in the blood signaling that cancer cells may still be active, was 3.5% (95% CI: 1.5–8.5%) [1]. In the subset of studies that included untreated controls, TRT was associated with a significantly lower recurrence risk compared to men who received no testosterone [1].
Put plainly: among the men studied, very few saw their PSA come back after surgery, and those who got testosterone did no worse than those who did not.
NOT SURE WHERE TO START?
Take our 2-minute hormone & metabolism quiz to see exactly where you stand. Or skip ahead — a $49 lab panel gives you the numbers, a free hormone screen gives you a plan.
The signal is cautiously reassuring. A pooled rate of 3.5% is low by any clinical measure, and the direction of the comparison with controls runs opposite to what the old fear predicted [1]. A broader 2020 meta-analysis in Urologic Oncology that looked at 21 studies of men after definitive local treatment reported a similarly low pooled biochemical recurrence rate, finding "a lack of association between TRT and BCR" [3]. A 2025 systematic review in BJU International added that recurrence rates in TRT-exposed cohorts post-surgery ranged from 0% to 7%, with follow-up as long as 60 months, without a significant difference from non-exposed comparators [2].
The 2026 authors are transparent about what their data cannot answer [1]:
None of this erases the finding. It does mean the finding belongs in a specific category: hypothesis-strengthening, not hypothesis-settling. The practical question, who is a reasonable candidate for this conversation with their physician, depends
The practical answer depends on two things: how far the cancer has been from active disease, and how clearly symptomatic the testosterone deficiency is. Both matter equally. A man who checks every oncological box but has no real hypogonadal symptoms has little reason to take on any added monitoring burden. A man with documented symptoms and a favorable post-surgical course is exactly the population these studies enrolled.
The meta-analysis in Andrology (2026) drew from men with a pooled biochemical recurrence rate of 3.5% (95% CI: 1.5–8.5%) [1], and the broader 2020 systematic review in Urologic Oncology reported a pooled recurrence rate near zero in post-radical prostatectomy patients who received TRT [3]. The common thread across both bodies of evidence: favorable pathology and a sustained undetectable PSA before starting therapy.
| Clinical Factor | More Favorable | Less Favorable |
|---|---|---|
| Gleason score (tumor aggressiveness grade) | 6 or low-grade group 1–2 | 8–10 or high-grade |
| PSA after surgery | Undetectable, sustained | Any detectable or rising PSA |
| Disease-free interval | Longer interval before TRT | Short interval, under 12 months |
| Pathological stage | Organ-confined disease, negative margins | Positive margins, seminal vesicle involvement |
| Hypogonadal symptoms | Clearly symptomatic, confirmed low testosterone | Borderline labs, minimal symptoms |
| Metastatic disease | No evidence of metastasis | Any metastatic spread |
Put plainly: the men likeliest to be reasonable candidates had low-grade, organ-confined cancer, a clean PSA after surgery, and symptoms that genuinely affect quality of life. You can find a breakdown of what those low testosterone symptoms actually look like, and whether age adds another layer of consideration, in the discussion of when TRT becomes worth considering.
What the table
If a physician clears a patient for TRT after prostatectomy, the prescription comes with a structured surveillance schedule, not a handshake and a see-you-in-a-year. PSA is the primary signal clinicians watch, drawn at regular intervals because any meaningful rise is the first cue to pause, investigate, and reassess.
Research on post-prostatectomy biochemical recurrence shows how tightly testosterone recovery correlates with time and hormonal context. A 2022 randomized phase 2 trial published in European Urology Open Science found that median time to testosterone recovery after androgen deprivation varied by regimen, reaching as long as 52.9 weeks in some arms [7]. That timeline illustrates why restoration requires patience and close tracking, not just a single lab draw.
A standard monitoring checklist in this setting typically includes:
Put plainly: this is a protocol with checkpoints, not a set-and-forget prescription. Understanding how to read your hormone lab report helps patients stay active partners in that process, and the question of who qualifies in the first place is where patient selection becomes the real deciding factor.
Two conversations need to happen before anything else: one with your urologist, confirming oncological clearance, and one with a TRT physician who can weigh your hormone picture against your cancer history. Neither conversation replaces the other. Shared decision-making here means both specialists have seen your file.
The quality-of-life cost of untreated hypogonadism after surgery is real. A 2021 review in Sexual Medicine Reviews noted that testosterone deficiency following prostatectomy affects erectile function, energy, mood, and body composition, and that these effects are often underaddressed in post-surgical care [4]. That context belongs in your informed-consent conversation.
Bring these questions to your appointments:
Good decisions in this space come from complete information, not urgency. If you want to start that conversation, hormone therapy for men: benefits, side effects, and how it works provides useful grounding, and our team is available to review your case and labs together.
For carefully selected men who have had surgical removal of the prostate and have low testosterone with symptoms, recent evidence is cautiously reassuring. A 2026 meta-analysis found a biochemical recurrence rate of 3.5% among hypogonadal men who received testosterone therapy after surgery. Multiple systematic reviews report similarly low recurrence rates, ranging from 0% to 7%. However, no randomized controlled trials exist yet, and follow-up periods have been relatively short, so the evidence strengthens the hypothesis but does not settle it definitively. Your decision should involve both your urologist and a testosterone-experienced physician.
Prostate cancer treatment, not the cancer itself, usually causes low testosterone. Surgery, radiation, and especially androgen deprivation therapy (ADT, drugs that suppress testosterone to starve remaining cancer cells) all disrupt the pituitary-gonadal axis, the brain-to-testicles signaling chain that controls testosterone production. This disruption leads to fatigue that rest does not fix, loss of muscle mass, low libido, erectile difficulty, and cognitive fog. Recovery after stopping ADT is uncertain. A 2019 study found only 55.2% of men regained normal testosterone levels, with older age and longer ADT duration predicting slower recovery.
The old belief that any testosterone accelerates prostate cancer was oversimplified. The saturation model explains that prostate cells contain receptors that reach full activation at testosterone levels well below the normal range. Once saturated, adding more testosterone produces little additional effect on prostate tissue, much like a sponge absorbing water only to a point. This means castration-level testosterone dramatically suppresses cancer growth, but testosterone in the normal physiologic range produces little incremental effect on prostate activity. PSA does not rise predictably when hypogonadal men are restored to normal levels after surgery.
The best candidates have low-grade, organ-confined cancer, an undetectable PSA sustained for months after surgery, clear hypogonadal symptoms that affect quality of life, and no evidence of metastatic disease. Less favorable candidates have high Gleason scores, any detectable or rising PSA, positive surgical margins, or symptoms that are borderline. A longer disease-free interval before starting testosterone is also more favorable than a short one. Selection depends equally on favorable cancer pathology and genuine, confirmed testosterone deficiency with real symptoms.
Testosterone therapy after prostatectomy requires structured surveillance, not a single check-in. Standard monitoring includes PSA every 3 months for the first year, then every 6 months if stable; total and free testosterone at each visit with dose adjusted by symptom response; hematocrit checked at baseline and every 3 months because elevated red blood cell counts can become a safety concern; and estradiol monitored to prevent over-conversion of testosterone to estrogen. This is a protocol with regular checkpoints where both your urologist and prescribing physician should coordinate care.
Take our 2-minute hormone & metabolism quiz to see exactly where you stand — or jump straight to labs or a free screen with our team.